News | March 19, 2024
Grace expands CDMO capacity by 25% of South Haven facility in Michigan
Additional capacity broadens Grace’s fine chemical capabilities for API production
Additional capacity broadens Grace’s fine chemical capabilities for API production
PharmaLogic will assist ARTBIO with radiochemistry and supply of the finished radiopharmaceutical product for future Phase I and II clinical trials of AB001 from their facility in New York
This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy
The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
Honeywell Solstice Air is a hydrofluoroolefin (HFO) propellant in clinical development today for pMDIs
Evonik specializes in mid- to large-scale, later clinical phase HPAPIs
As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
Subscribe To Our Newsletter & Stay Updated
